Celularity (CELU) Competitors

LifeVantage (NASDAQ:LFVN) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Which has preferable earnings & valuation, LFVN or CELU?

LifeVantage has higher revenue and earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeVantage	$222.35M	0.71	$2.94M	$0.69	18.20
Celularity	$48.20M	1.00	-$196.29M	-$2.65	-0.76

Does the MarketBeat Community favor LFVN or CELU?

LifeVantage received 215 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 77.97% of users gave LifeVantage an outperform vote while only 42.11% of users gave Celularity an outperform vote.

Company	Underperform	Outperform
LifeVantage	Outperform Votes 223 77.97%	Underperform Votes 63 22.03%
Celularity	Outperform Votes 8 42.11%	Underperform Votes 11 57.89%

Do institutionals & insiders have more ownership in LFVN or CELU?

35.3% of LifeVantage shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 20.7% of LifeVantage shares are held by company insiders. Comparatively, 22.1% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has more risk and volatility, LFVN or CELU?

LifeVantage has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Is LFVN or CELU more profitable?

LifeVantage has a net margin of 3.46% compared to Celularity's net margin of -72.72%. LifeVantage's return on equity of 34.29% beat Celularity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeVantage	3.46%	34.29%	15.04%
Celularity	-72.72%	-119.53%	-25.40%

Do analysts prefer LFVN or CELU?

LifeVantage currently has a consensus target price of $30.50, suggesting a potential upside of 142.83%. Given LifeVantage's stronger consensus rating and higher probable upside, equities analysts clearly believe LifeVantage is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeVantage	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Celularity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media favor LFVN or CELU?

In the previous week, LifeVantage had 3 more articles in the media than Celularity. MarketBeat recorded 8 mentions for LifeVantage and 5 mentions for Celularity. Celularity's average media sentiment score of 1.37 beat LifeVantage's score of 0.79 indicating that Celularity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeVantage	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celularity	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LifeVantage beats Celularity on 14 of the 18 factors compared between the two stocks.